[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599109":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":64,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":26,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"PART 1（phaseⅠ）","EXPERIMENTAL","Part 1 is a dose exploratory study of ZG005 combined with gecaxitinib ± bevacizumab to evaluate the tolerability and safety of the combination regimen",[13,14,15],"Biological: ZG005","Drug: Gecacitinib","Biological: Bevacizumab",{"label":17,"type":10,"description":18,"interventionNames":19},"PART 2（phase II）","Part 2 is a dose expansion study to further evaluate the safety and preliminary efficacy of the combination regimen identified in Part 1",[13,14,15],[21,27,32],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","ZG005","ZG005 20mg\u002Fkg, intravenous infusion(IV), once every 3 weeks (Q3W)",[9,17],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DRUG","Gecacitinib","Part 1: Cohort A：Gecacitinib is administered continuously until the end of treatment; Cohort B：Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21；Part 2：Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.",[9,17],{"type":22,"name":33,"description":34,"armGroupLabels":35,"otherNames":26},"Bevacizumab","Bevacizumab 7.5 mg\u002Fkg，intravenous infusion(IV), once every 3 weeks (Q3W)",[9,17],[37],{"name":38,"affiliation":5,"role":39},"Jason Wu","STUDY_CHAIR",[41],{"name":42,"role":43,"phone":44,"phoneExt":26,"email":45},"Yongsheng Chu","CONTACT","+86-0512-57309965","chuys@zelgen.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Zhejiang Cancer Hospital","RECRUITING","Hangzhou","Zhejiang","310022","China","CN",{"type":56,"coordinates":57},"Point",[58,59],120.16142,30.29365,{"lat":59,"lon":58},[62],{"name":63,"role":43,"phone":26,"phoneExt":26,"email":26},"Hanmei Lou",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100599109","phase-1-study-of-zg005-in-combination-with-gecacitinib-in-participants-with-advanced-cervical-cancer-100599109",false,"NCT07080216","Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I\u002FII Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form.\n* Female 18-75 years of age;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Histologically or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n\nExclusion Criteria:\n\n* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.","FEMALE","18 Years","75 Years",{"count":77,"type":78},120,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE1","PHASE2","This is a multicenter, open-label phase I\u002FII study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.",[85],"Cervical Cancer","2025-12-30",{"date":88,"type":89},"2026-01-05","ACTUAL",{"date":91,"type":89},"2025-09-23",{"date":93,"type":78},"2027-12",{"name":5,"class":6},1]